(0.27%) 5 168.75 points
(0.22%) 38 918 points
(0.26%) 18 048 points
(1.09%) $78.96
(0.56%) $2.15
(0.91%) $2 329.70
(2.65%) $27.40
(1.17%) $976.55
(-0.02%) $0.929
(-0.21%) $10.85
(-0.26%) $0.795
(0.00%) $91.46
3 days till quarter result
(bmo 2024-05-09)
Expected move: +/- 0.00%
0.68% ¥ 149.00
Live Chart Being Loaded With Signals
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States...
Stats | |
---|---|
Dzisiejszy wolumen | 386 100 |
Średni wolumen | 1.41M |
Kapitalizacja rynkowa | 13.43B |
EPS | ¥0 ( 2024-02-13 ) |
Następna data zysków | ( ¥-4.96 ) 2024-05-09 |
Last Dividend | ¥0 ( N/A ) |
Next Dividend | ¥0 ( N/A ) |
P/E | -2.65 |
ATR14 | ¥0.366 (0.24%) |
Wolumen Korelacja
Healios K.K. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Healios K.K. Korelacja - Waluta/Towar
Healios K.K. Finanse
Annual | 2023 |
Przychody: | ¥121.00M |
Zysk brutto: | ¥-265.00M (-219.01 %) |
EPS: | ¥-56.22 |
FY | 2023 |
Przychody: | ¥121.00M |
Zysk brutto: | ¥-265.00M (-219.01 %) |
EPS: | ¥-56.22 |
FY | 2022 |
Przychody: | ¥90.00M |
Zysk brutto: | ¥90.00M (100.00 %) |
EPS: | ¥-90.69 |
FY | 2021 |
Przychody: | ¥41.00M |
Zysk brutto: | ¥41.00M (100.00 %) |
EPS: | ¥-46.81 |
Financial Reports:
No articles found.
Healios K.K.
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej